Ocular Toxoplasmosis

Permanent central vision loss

The most clinically significant complication. Occurs when active retinochoroiditis involves the fovea, papillomacular bundle, or optic nerve. Studies by Bonfioli and Orefice (2005) found that 24% of patients with macular lesions lost two or more Snellen lines permanently. Lesion size >1 DD and juxtafoveal or subfoveal location are the strongest predictors of irreversible central vision loss. Even with appropriate antiparasitic treatment, the resulting chorioretinal scar in the macula causes a permanent scotoma proportional to scar extent.

Recurrent flares — the greatest long-term threat

The risk of disease recurrence is the dominant prognostic concern in ocular toxoplasmosis. The Toxoplasmic Retinochoroiditis Study reported a recurrence rate of 50% at 3 years and 79% at 10 years (Bosch-Driessen et al.). Each recurrence risks forming new scars in previously uninvolved retinal areas and progressively encroaching on the macula, particularly when the original scar is adjacent to the vascular arcades. Recurrence risk is higher in females, those from high-endemicity regions, and those with prior macular involvement.

Rhegmatogenous and tractional retinal detachment

Chorioretinal scars create focal areas of firm vitreoretinal adhesion. Vitreous traction at the scar margin during posterior vitreous detachment (PVD) may avulse the retina, creating a tear and subsequent rhegmatogenous detachment. Dense fibrovascular proliferation in severe or recurrent disease can produce tractional detachment without a retinal break. Either mechanism may cause sudden, profound visual loss requiring urgent vitreoretinal surgical intervention.

Secondary choroidal neovascularisation (CNV)

CNV develops in approximately 2–10% of patients as a late complication of chorioretinal scarring, particularly when scars are large or juxtafoveal. CNV causes subretinal fluid, haemorrhage, and lipid exudation threatening the fovea. OCT angiography (OCTA) is sensitive for detecting early CNV. Treatment follows standard anti-VEGF protocols (bevacizumab, ranibizumab, or aflibercept); however, CNV secondary to inflammatory scarring may have a more variable response than exudative AMD-related CNV.

Secondary glaucoma

IOP elevation occurs in approximately 10–15% of active cases through multiple mechanisms: inflammatory trabeculitis (aqueous protein and inflammatory cells obstructing trabecular meshwork), corticosteroid-induced IOP response (a significant concern given systemic prednisone use in management), and progressive peripheral anterior synechiae from chronic anterior uveitis. Secondary glaucoma may become sight-threatening independent of the retinochoroiditis. IOP measurement at every visit during active disease and treatment is mandatory.

Posterior subcapsular cataract

Develops from prolonged intraocular inflammation (inflammatory mediators disrupt the lens epithelium) and as a known side effect of systemic or topical corticosteroid therapy. Posterior subcapsular cataract (PSC) is the predominant morphology in this setting, causing disproportionate reduction in visual acuity and contrast sensitivity. Cataract surgery in the context of active or recently active uveitis requires careful planning to minimise post-operative inflammation.

Optic atrophy

Develops as a consequence of direct optic nerve involvement (juxtapapillary retinochoroiditis, papillitis) or chronic elevated IOP from secondary glaucoma. Once established, optic atrophy and the associated visual field loss are irreversible. Jensen's juxtapapillary toxoplasmic retinochoroiditis — a lesion at the disc margin — carries particularly high risk of permanent nasal visual field loss or central scotoma.

Cystoid macular oedema (CMO)

Inflammatory CMO may develop in response to active retinochoroiditis even when the lesion is peripheral to the macula. Inflammatory cytokines and prostaglandins disrupt the inner blood-retina barrier, causing intraretinal fluid accumulation in the perifoveal region. CMO is visualised on OCT as cystoid spaces in the inner nuclear and outer plexiform layers. It contributes to visual decline beyond the lesion itself and should be treated with topical NSAIDs, topical steroids, or intravitreal triamcinolone when antiparasitic treatment alone is insufficient.

Epiretinal membrane (ERM)

Fibrocellular membranes may form on the inner retinal surface as a consequence of localised inflammation and released growth factors. ERMs cause metamorphopsia, reduced contrast sensitivity, and occasionally significant visual acuity loss independent of the primary lesion. Mild ERMs can be observed; surgically significant ERMs causing distortion or acuity loss are managed by pars plana vitrectomy with membrane peeling once the eye has been quiescent for at least 3–6 months.

Phthisis bulbi

End-stage consequence of severe, repeatedly recurrent, or inadequately treated bilateral disease. Global hypotony from ciliary body destruction and retinal detachment leads to progressive ocular shrinkage, corneal opacification, and eventual structural disorganisation. Rare in immunocompetent patients receiving appropriate care; more common in immunocompromised patients or those without access to treatment.

Congenital Toxoplasmosis — the Sabin Triad and Beyond

The classic triad of congenital toxoplasmosis (described by Sabin, 1941) consists of chorioretinitis, diffuse intracranial calcifications, and hydrocephalus. However, the clinical spectrum is broad: severe disease (the classic triad) occurs in <10% of congenitally infected children; most are subclinically affected at birth but may develop reactivation retinochoroiditis years to decades later. Additional manifestations include microcephaly, microphthalmia, nystagmus, strabismus, sensorineural hearing loss, cognitive impairment, seizures, and motor deficits. Bilateral, large macular scars are more common in congenital disease than in postnatally acquired cases. Risk of severe disease is highest with first-trimester maternal infection despite the lower transmission rate (~15%) at that gestational age.

Primary Acquired Infection in Immunocompetent Adults

In immunocompetent individuals, acute primary infection is asymptomatic in approximately 80–90% of cases. Symptomatic primary infection most commonly presents as a mononucleosis-like illness: cervical lymphadenopathy (single or bilateral, non-tender), low-grade fever, malaise, myalgia, and headache. Severe primary infection with pneumonitis, myocarditis, hepatitis, encephalitis, or disseminated disease is rare but documented in immunocompetent patients, particularly with virulent South American strains. Ocular involvement may manifest months to years after primary systemic infection as the tissue cysts undergo reactivation.

HIV/AIDS and Ocular-Cerebral Co-involvement

Toxoplasmosis is the most common cause of focal brain lesions in HIV-infected patients, and ocular toxoplasmosis in AIDS frequently co-exists with cerebral toxoplasmosis. At CD4 counts <100 cells/µL, cysts in the brain and retina reactivate without effective containment. Cerebral toxoplasmosis presents with ring-enhancing lesions on MRI or contrast CT, headache, fever, focal neurological deficits, seizures, and altered consciousness. Ocular disease in AIDS is typically bilateral, multifocal, and rapidly progressive, with less vitritis than immunocompetent disease (due to blunted immune response) and may superficially resemble CMV retinitis. Any patient with ocular toxoplasmosis who lacks a known predisposing cause should be offered HIV testing in accordance with local public health guidelines.

Solid Organ and Stem Cell Transplantation

Seropositive donors (D+) transmitting to seronegative recipients (R−) carry the highest risk of primary disseminated toxoplasmosis post-transplant, particularly after heart transplantation (cardiac tissue has high bradyzoite cyst density). Primary disseminated disease in this setting can involve the brain, lungs, liver, heart, and eyes simultaneously, with high mortality. TMP-SMX prophylaxis for 6–12 months post-transplant is standard of care in D+/R− cardiac transplant recipients. Seropositive recipients receiving immunosuppression are at risk of reactivation.

Ocular Toxoplasmosis as a Systemic Alert

The optometrist encountering suspected ocular toxoplasmosis should consider systemic implications: (1) Bilateral or unusually severe disease — screen for HIV; (2) Features inconsistent with typical recurrent disease — consider immunosuppressed state including undiagnosed haematological malignancy; (3) Young patient with unexplained systemic lymphadenopathy and retinochoroiditis — primary acquired toxoplasmosis; (4) History of organ transplantation in any patient with posterior uveitis — consider donor-transmitted toxoplasmosis. All such patients require urgent medical referral.

Peripheral non-macular lesions — good prognosis

Excellent visual prognosis. Lesions remote from the fovea and papillomacular bundle heal with chorioretinal scarring that does not affect central vision or reading acuity. Symptoms — primarily floaters from vitritis — resolve over 4–8 weeks with or without treatment. Observation is appropriate for small peripheral lesions in immunocompetent patients; active peripheral lesions are treated to prevent enlargement and reduce recurrence risk at that site.

Macular and papillomacular lesions — guarded prognosis

Lesion location is the dominant determinant of final visual acuity. Foveal involvement carries the worst prognosis — even with prompt and effective antiparasitic treatment, the resulting scar causes a permanent central scotoma proportional to its size. Bonfioli and Orefice (2005) found that 24% of patients with macular lesions lost ≥2 Snellen lines permanently. The papillomacular bundle, when scarred, causes central and paracentral field loss that profoundly affects reading and daily function. Early initiation of treatment remains the best strategy to limit the extent of necrotising damage.

Recurrence risk — the greatest long-term determinant

Recurrence is the dominant prognosis modifier. The Bosch-Driessen et al. prospective cohort (2002) reported 50% recurrence at 3 years and 79% at 10 years without prophylaxis. Each recurrence adds a new scar, potentially in a new anatomical location. Cumulative macular scar burden from repeated episodes is the mechanism by which previously peripheral disease eventually threatens central vision. Risk factors for higher recurrence: female sex, young age of first episode, residence in South America, prior macular lesion, absence of TMP-SMX prophylaxis.

Effect of TMP-SMX prophylaxis on recurrence

The TPMT randomised controlled trial (Silveira et al., 2002) demonstrated a 62% reduction in recurrence rate with TMP-SMX 160/800 mg three times weekly (6.6% vs 23.8% recurrence at 20 months, p<0.001). This represents a major improvement in long-term prognosis for high-risk patients. Prophylaxis does not eradicate tissue cysts but suppresses tachyzoite reactivation, extending recurrence-free intervals and allowing macular recovery without new scar formation.

Visual acuity outcomes — published evidence

A Cochrane review (Stanford et al.) on interventions for ocular toxoplasmosis found that antiparasitic therapy reduces lesion size and duration of active disease compared to placebo, though definitive evidence of improved final visual acuity in peripheral lesions is limited by natural resolution. For vision-threatening lesions, expert consensus and observational evidence strongly support early treatment. The Soheilian et al. (2005) RCT showed comparable lesion size reduction between TMP-SMX and pyrimethamine-sulfadiazine-prednisolone.

Immunocompromised patients — significantly worse prognosis

HIV-positive patients with CD4 <100 cells/µL face the worst prognosis: bilateral multifocal disease, rapid progression, high mortality if CNS co-involvement is present, and high recurrence rate after treatment. Immune reconstitution with antiretroviral therapy (ART) to restore CD4 >200 cells/µL is the most important long-term intervention. With immune recovery, secondary prophylaxis may eventually be discontinued under specialist supervision. Without ART or with persistent immunosuppression, indefinite antiparasitic prophylaxis is required.

Congenital disease — late reactivation is an underappreciated risk

Congenitally infected children who appear visually and neurologically normal in early childhood may develop reactivation retinochoroiditis during adolescence or early adulthood as local retinal immunity wanes. Rates of late reactivation in congenital disease reach 45–85% by adulthood in untreated cohorts. Bilateral macular involvement from congenital disease significantly impairs the development of binocular vision and stereopsis, and strabismus is common. Long-term ophthalmological follow-up throughout childhood and adolescence is essential in confirmed congenital cases.

Key favourable prognostic factors

Peripheral lesion location; lesion <1 DD; prompt treatment initiation (<1 week from symptom onset); normal immune status; Type II strain genotype (European); absence of macular or optic nerve involvement; adherence to TMP-SMX prophylaxis; regular follow-up.

Key poor prognostic factors

Macular, juxtafoveal, or juxtapapillary lesion location; large lesion size (>2 DD); CD4 <100 cells/µL; bilateral disease; treatment delay >2 weeks; Type I or recombinant South American parasite strain; non-adherence to prophylaxis; prior history of multiple recurrences with cumulative macular scar burden.